Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Joshua S. George"'
Autor:
Joshua S. George, Jeffrey Johnson
Publikováno v:
BMC Pregnancy and Childbirth, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Women with pre-existing forms of familial cardiomyopathy are at increased risk for morbidity and mortality due to hemodynamic changes of pregnancy. There is a lack of consensus about the management and care for these patients give
Externí odkaz:
https://doaj.org/article/14a77eee820c4c798a7a015a261f8331
Publikováno v:
Obstetrics & Gynecology. 139:91S-91S
Publikováno v:
Obstetrics & Gynecology. 139:48S-48S
Autor:
Anastasia Godur, Joshua S. George, D. Jeffrey Newport, Blaine Menon, JoNell Potter, Stephen Symes, Sana Malik, Ira Karmin, Grechen Mills, Panagiota V. Caralis
Publikováno v:
Journal of Human Trafficking. 6:50-60
Introduction: The THRIVE Clinic provides medical/psychiatric care for human trafficking survivors in Miami. Designed to address the comprehensive healthcare needs of this unique population, the cli...
Autor:
Francesca N. Raffa, Dipan D. Desai, Erin R. Cohen, Monika E. Freiser, Mikhaylo Szczupak, Zoukaa Sargi, Kaming Lo, Chetan S. Nayak, Donald T. Weed, Patrick M. Azcarate, Joshua S. George
Publikováno v:
Otolaryngology–Head and Neck Surgery. 154:638-644
To evaluate improvement of medical student knowledge of head and neck cancer (HNC) through participation in HNC screening fairs run by medical students.Prospective cohort study of surveys assessing medical students' knowledge of HNC before and after
Autor:
Panagiota V. Caralis, Joshua S. George, JoNell Potter, Megan Mathew, Stephen Symes, Lujain Alhajji
Publikováno v:
Obstetrics & Gynecology. 133:153S-153S
Autor:
Stephanie Galban, Craig J. Galbán, Benjamin A. Hoff, Joshua S. George, Jean-Christophe Brisset, Brian D. Ross, Alnawaz Rehemtulla
Publikováno v:
Cancer Research. 73:5595-5595
Approximately 70% of patients with late stage cancers metastasize to the bone. RECIST identifies these tumors as “unmeasureable” for therapeutic response assessment. Cabozantinib (CABO), a tyrosine kinase inhibitor of MET and VEGFR2, has shown pr